grant
Design of a Novel Nanocarrier Technology to Drug-Load CAR T cells
Organization UNIVERSITY OF KANSAS MEDICAL CENTERLocation KANSAS CITY, UNITED STATESPosted 1 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY202521+ years oldAbscissionAddressAdjuvantAdoptive Cell TransfersAdultAdult HumanAffectAntibody SpecificityAntimorphic mutationB7-H1BiochemicalBleedingBrain CancerBrain NeoplasiaBrain NeoplasmsBrain TumorsCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD274CancersCell BodyCell FunctionCell PhysiologyCell ProcessCell SurvivalCell ViabilityCellsCellular FunctionCellular PhysiologyCellular ProcessCessation of lifeChimera ProteinChimeric ProteinsClinicalClinical EvaluationClinical TestingClinical TrialsCytolysisDataDeathDiseaseDisorderDoctor of PhilosophyDominant NegativeDominant-Negative MutantDominant-Negative MutationDrug UtilizationDrug toxicityDrug vehicleDrugsEGF ReceptorEGFRERBB ProteinEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor KinaseEpidermal Growth Factor Receptor Protein-Tyrosine KinaseEpidermal Growth Factor-Urogastrone ReceptorsEstersEvaluationExcisionExtirpationFDA approvedFusion ProteinGingivaGingivalGlioblastomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGrowth Factor InhibitionGrowth Factor ReceptorsHER1Half-LifeHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHemorrhageHistiocytosisImmuneImmunesIn VitroIntracranial HemorrhagesKansasKinasesLabelLaboratoriesLifeLysisMacrophageMalignant Hematologic NeoplasmMalignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant neoplasm of brainMalignant neoplasm of prostateMalignant prostatic tumorMediatingMedicationMiceMice MammalsModelingMurineMusMφNanoplatformNanotechnological platformNanotechnologyOncogenicPD-L1PDL-1PatientsPenetrationPeptidesPh.D.PhDPharmaceutical PreparationsPhosphotransferase GenePhosphotransferasesPolymersPre-Clinical ModelPreclinical ModelsPrincipal InvestigatorProductionProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1Prostate CAProstate CancerProstate malignancyReceptor ProteinRecurrenceRecurrentRemovalReportingResearchResistanceRouteSolid NeoplasmSolid TumorSubcellular ProcessSurgical RemovalT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyTGF-alpha ReceptorTechnologyTestingTherapeuticToxic effectToxicitiesTransforming Growth Factor alpha ReceptorTransforming Growth FactorsTransphosphorylasesTumor Growth FactorsUniversitiesUpregulationUrogastrone Receptoradoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyadoptive cell therapyadoptive cellular therapyadulthoodblood lossc-erbB-1c-erbB-1 Proteincancer microenvironmentcell killingchemo-/radio-therapychemo-radiotherapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapychimeric antigen T cell receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical testcomparable efficacycomparative efficacycompare efficacycytokinedesigndesigningdosagedrug candidatedrug/agenterbB-1erbB-1 Proto-Oncogene ProteinerbBlexperienceglioblastoma multiformeimmunotoxicityimprovedin vivoinhibitorinterestinventionkinase inhibitormalignancymanufacturenano technano technologynano-technologicalnanocarriernanotechnanotechnologicalnanotechnology platformnanovesselneoplasm/cancernew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetoverexpressoverexpressionpolymerpolymericpre-clinicalpreclinicalprogrammed cell death ligand 1programmed cell death protein ligand 1protein death-ligand 1proto-oncogene protein c-erbB-1radio-chemo-therapyradio-chemotherapyradiochemotherapyreceptorresearch clinical testingresectionresistantresponsesmall molecular inhibitorsmall moleculesmall molecule inhibitorspongioblastoma multiformesuccesssystemic toxicitytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttechnology platformtechnology systemtherapeutic T-cell platformtherapeutic targetthymus derived lymphocytetoxic reaction in immunologytransforming growth factors Animal growth regulatorstumortumor eradicationtumor microenvironmenttumor specificitytumors in the brainuptake
Description preview
Project summary:
Current treatment for Glioblastoma Multiforme (GBM), the most common malignant brain tumor in adults,
involves maximal safe resection, followed by adjuvant chemoradiation. Although this treatment is life prolonging,
it is never curative. Five year survival is less than 7 %1 and improved therapies are urgently needed. In this…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click